

PROSTATE CANCER SCREENING

- \checkmark Over 80% of men ages 70-79 have occult, insignificant prostate cancer at autopsy.
- Only one of three trials, European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a screening \checkmark benefit.
- ✓ In the ERSPC Trial, 781 men were screened, and 27 men were treated for prostate cancer in order to save one prostate cancer life 13 years after screening.¹
- PSA screening should stop at age 69.

PROSTATE CANCER TREATMENT

- The disease specific survival of Gleason 6 prostate cancer using active surveillance at 10 years is 98%.²
- 63% of patients started on active surveillance will not need treatment over at least 10 years.² \checkmark
- For localized prostate cancer, survival advantage of surgery over observation was only 4% at 20 year follow up.³ \checkmark
- Urologist ownership of radiation therapy centers may influence decision to use radiation therapy for treatment.⁴
- \checkmark Five years out from surgery, the impotence rate is over 75% and bladder leakage rate is over 25%.⁵
- Five years out from radiation therapy, the impotence rate is over 70% and rectal urgency rate is over 30%.⁵

In summary:

- Understand the large risks and small benefits to screening.
- Shared decision making is essential.
- If your patient is diagnosed with prostate cancer, do not assume optimal care will be utilized so consider the following:



OVERACTIVE BLADDER (OAB) TREATMENT

- Optimally managed with behavioral modification (bladder training, pelvic floor exercises, eliminate bladder irritants). \checkmark
- \checkmark Drugs for OAB are only modestly effective with a high rate of side effects.
- Brand name drugs cost \$4,000 to \$6,000 yearly and patients self-discontinue over 70% of the time within one year.⁶ \checkmark

OPTIMAL RENAL STONE MANAGMENT

- Management is through PCP or urgent outpatient urology evaluation.
- The emergency room is infrequently necessary. \checkmark
- ✓ Tamsulosin is of no benefit for stones <5mm in diameter.
- 67% of stones <5mm will spontaneously pass in four weeks. \checkmark
- Oral potassium citrate reduces recurrent calcium stone formation by up to 75%. \checkmark
- 1. The Lancet, 2014;384(9959):2027-2035. doi:10.1016/S0140-6736(14)60525-0
- 2. Journal of Clinical Oncology. 2015;33(3):272-277. doi:10.1200/JCO.2014.55.1192
- European Urology. 2020;77(6):713-724. doi: 10.1016/j.eururo.2020.02.009
 New England Journal of Medicine. 2013;369(17):1629-1637. doi:10.1056/NEJMsa1201141
- 5. New England Journal of Medicine. 2013;368(5):436-445. doi:10.1056/NEJMoa1209978
- 6. GoodRx, Inc (2018) Retrieved from GoodRx Web site: https://www.goodrx.com/

